Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $10.60

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.20.

HCAT has been the topic of several analyst reports. Royal Bank of Canada dropped their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 15th. Wells Fargo & Company lowered their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Citigroup reduced their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Piper Sandler lowered their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Stephens boosted their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the sale, the insider now directly owns 92,260 shares of the company’s stock, valued at $535,108. This represents a 6.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total transaction of $30,003.84. Following the transaction, the chief operating officer now owns 86,044 shares in the company, valued at approximately $495,613.44. The trade was a 5.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,169 shares of company stock valued at $629,068 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently made changes to their positions in HCAT. Impax Asset Management Group plc raised its holdings in Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Primecap Management Co. CA raised its stake in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares in the last quarter. Nepsis Inc. lifted its position in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares during the period. Geode Capital Management LLC boosted its stake in Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after buying an additional 66,896 shares in the last quarter. Finally, State Street Corp increased its holdings in Health Catalyst by 2.5% in the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after buying an additional 28,251 shares during the period. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Trading Down 1.1 %

NASDAQ:HCAT opened at $5.44 on Friday. The company has a market capitalization of $331.02 million, a P/E ratio of -4.03 and a beta of 1.34. The stock’s 50 day moving average price is $6.69 and its 200 day moving average price is $7.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 52 week low of $5.32 and a 52 week high of $10.14.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.